Why 80% of Sleep Apnea Goes Undiagnosed, and Who Pays the Price

Here's a statistic that should be more alarming than it is: of all the Americans living with obstructive sleep apnea, roughly 80 percent have never been diagnosed. Not misdiagnosed. Not poorly treated. Simply never identified at all, walking around with a serious, progressive, treatable medical condition that no one, including them, has named.

Imagine that ratio for almost any other major disease. If four out of five people with diabetes, or with high blood pressure, had no idea they had it, we'd call it a public health emergency and mean it. With sleep apnea, we've somehow normalized it. The condition is so common, so quiet, and so easy to wave away as ordinary tiredness that a massive undiagnosed population has become the accepted background state of the country.

It shouldn't be. Because that 80 percent isn't a harmless statistic. It represents an enormous, largely preventable burden of disease, cost, and risk, and, as with most gaps in American healthcare, the weight of it doesn't fall evenly. Let's look at how big the undiagnosed population really is, why it stays hidden, what it costs, and, most importantly, who ends up paying.

Just how many people are we talking about?

The exact number depends on which prevalence estimate you use, and all of them are large. For years the widely cited figure, used by the American Academy of Sleep Medicine, was that around 30 million American adults have obstructive sleep apnea, with roughly 80 percent undiagnosed ^[1]. That conservative version alone means well over 20 million people with an unrecognized condition.

More recent modeling suggests even that undercounts it. As obesity rates have climbed and researchers have refined their methods, newer estimates put the number of US adults with OSA far higher, with some 2024 analyses estimating more than 80 million affected, again with about 80 percent undiagnosed ^{[2, 3]}. An international review recently estimated that nearly a billion adults worldwide have the condition ^[4].

Whatever the precise figure, the shape of it is consistent and striking: the diagnosed patients are a small minority sitting atop a vast, mostly invisible population of people who have it and don't know. The people getting treated are the tip; the undiagnosed are the iceberg.

Why it stays hidden

A disease this common and this consequential doesn't stay undiagnosed by accident. Several features of sleep apnea conspire to keep it invisible.

It happens while you're asleep. This is the obvious but underrated one. The core events of sleep apnea, the airway collapsing, the oxygen dropping, the brief arousals to resume breathing, all occur when you're unconscious and can't observe them. Most people with the condition have no memory of the dozens or hundreds of nightly interruptions. Without a bed partner to witness the gasping or the pauses in breathing, there may be no obvious sign at all.

Its symptoms masquerade as ordinary life. The daytime consequences, fatigue, low energy, irritability, brain fog, morning headaches, trouble concentrating, are vague and universal. They're easy to blame on stress, a demanding job, poor diet, getting older, or simply not sleeping enough. A person can attribute years of exhaustion to their busy life and never suspect a medical cause. The symptoms don't point clearly at sleep apnea the way chest pain points at the heart.

It develops slowly. Sleep apnea creeps in over years, often alongside gradual weight gain. There's rarely a dramatic moment that sends someone to the doctor. The frog-in-boiling-water quality means people adapt to feeling progressively worse, recalibrating their sense of "normal" downward without noticing.

The old diagnostic path was a barrier in itself. For decades, getting diagnosed meant a referral to a scarce specialist and a night in a sleep lab, expensive, inconvenient, and geographically out of reach for many. When the path to a diagnosis is that arduous, plenty of people who suspect something never pursue it, and plenty of primary care providers, stretched thin, don't push a symptomatic patient down a road they know is long.

Add these together and you get a disease almost engineered to hide: silent at night, disguised by day, slow to develop, and historically hard to test for.

What it costs

The instinct might be to think of undiagnosed sleep apnea as a quality-of-life issue, people who are more tired than they need to be. That dramatically understates it. The costs are measured in dollars, in accidents, and in downstream disease, and they are staggering.

A detailed analysis commissioned by the AASM and conducted by the research firm Frost & Sullivan estimated the annual economic burden of undiagnosed obstructive sleep apnea in US adults at roughly $150 billion ^{[5, 6]}. The breakdown is sobering: about $87 billion in lost productivity and absenteeism, $26 billion tied to motor vehicle accidents, $6.5 billion in workplace accidents, and $30 billion in the increased healthcare costs of the conditions untreated apnea aggravates ^{[5, 6]}. Notably, the same analysis estimated that diagnosing and treating every affected adult would cost far less than the burden of leaving them undiagnosed ^[7]. Ignoring the problem is more expensive than fixing it.

Behind those dollar figures are real harms:

Accidents. Untreated sleep apnea causes daytime drowsiness that measurably raises the risk of car crashes. Research has attributed hundreds of thousands of motor vehicle collisions and thousands of deaths per year to the condition, and shown that effective treatment sharply reduces that risk ^[8]. When an undiagnosed driver falls asleep at the wheel, the price is paid not only by them but by everyone on the road.

Downstream disease. This is the big one. Untreated sleep apnea is a documented driver of high blood pressure, and it worsens the risk of heart disease, stroke, type 2 diabetes, atrial fibrillation, and cognitive decline. Every year an apnea goes undiagnosed is a year it quietly aggravates these other conditions, many of which are far more expensive and dangerous to treat than the apnea itself. The undiagnosed 80 percent aren't just tired; they're accumulating cardiovascular and metabolic damage that will surface later as heart attacks, strokes, and diabetes.

The tragedy is that this is among the more treatable chronic conditions in medicine. The cost isn't the price of an incurable disease. It's the price of one we're simply failing to find.

Who pays the price

Now to the part that makes this a health equity issue and not just a public health one. The undiagnosed 80 percent is not a random slice of the population. Diagnosis flows toward those with resources and access, which means the burden of remaining undiagnosed flows toward those without.

Consider who is least likely to get diagnosed. People without a regular doctor or good insurance, who never get the referral in the first place. People in rural areas, where sleep specialists and accredited labs are scarce and the nearest facility may be hours away. People in lower-income communities, where taking time off for a sleep study, or affording one, is a real barrier. People whose symptoms get dismissed, and there is documented evidence that sleep apnea is under-recognized in women and in some racial and ethnic minority groups, partly because it doesn't always match the stereotyped picture of the condition. And people who don't fit the "obvious" profile at all, like those with a normal-looking weight whose risk gets overlooked entirely.

These are, to a striking degree, the same populations already underserved across the rest of the healthcare system. So undiagnosed sleep apnea doesn't just distribute its harm unevenly; it piles additional harm onto communities that are already carrying more than their share of untreated disease. The rural patient with undiagnosed apnea is also, statistically, more likely to have untreated hypertension and diabetes, and the apnea is quietly making both worse. The gap compounds.

That's what turns a diagnostic shortfall into an equity problem. Two people can have the same condition, the same severity, the same risk, and face completely different odds of ever being identified and helped, with the deciding factors being income, geography, insurance, gender, and whether they happen to fit a doctor's mental image of a sleep apnea patient. None of those factors is biological. All of them are fixable.

Closing the gap

The encouraging news is that the single biggest historical barrier, the difficulty of getting tested, is exactly what's changing, and the changes disproportionately help the people who were being left out.

Home sleep testing now allows many people to be evaluated for sleep apnea in their own beds, without a specialist referral, an overnight lab stay, or a long drive, removing the cost and access barriers that kept so many from ever getting tested. Telemedicine lets a specialist reach patients in communities that have none of their own. Better screening tools, deployed through primary care and technology rather than requiring a specialist at every step, mean more of the symptomatic 80 percent can actually be flagged and evaluated. And a broader clinical shift toward looking past the stereotype, taking symptoms seriously in women, in normal-weight patients, and in anyone with the warning signs regardless of whether they "look" like they have apnea, helps catch the cases the old mental model missed.

None of this erases every barrier overnight. But the direction is right: the tools now exist to find a large share of that hidden 80 percent, if the will and the systems are there to reach them.

Where SOMOS fits

This is precisely the gap SOMOS was built to close, and why we treat it as a matter of equity. An 80 percent undiagnosed rate isn't a fact of nature; it's the product of a system where getting identified and treated has depended too heavily on your access, your income, and whether you fit the expected profile. Our aim is to make finding and treating sleep apnea, along with the metabolic conditions tangled up with it, straightforward and reachable through home-based assessment, remote access to expert care, and technology that extends how far that care can travel, with follow-up over time rather than a single visit. The goal is to shrink that 80 percent by reaching the people the old system was most likely to skip, so that a diagnosis stops depending on privilege.

The bottom line

Roughly four out of five Americans with obstructive sleep apnea have never been diagnosed, a hidden population in the tens of millions, carrying a condition that quietly drives heart disease, stroke, diabetes, accidents, and an economic burden estimated around $150 billion a year. It stays hidden because it happens in your sleep, disguises itself as ordinary tiredness, and has long been hard to test for. And the harm of staying hidden falls hardest on the people already underserved: the rural, the lower-income, the uninsured, and those who don't fit the stereotype. The condition is eminently treatable and, increasingly, easy to test for. The only real question is whether we build the systems to find the people who need it, especially the ones the old model was designed, however unintentionally, to miss.

This article is for general education and isn't a substitute for individual medical advice. If you have symptoms of sleep apnea, such as loud snoring, witnessed pauses in breathing, or persistent daytime fatigue, talk with a qualified clinician about getting evaluated.